DalsnaFinance

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Markets GlobeNewswire By GlobeNewswire 03 Jun 2026 13:45 1 min read
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.